61837-46-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-methylpentanoic Acid Methyl Ester is used as a synthetic intermediate for the production of a series of amino acids. Its application is particularly relevant in the pharmaceutical industry, where these amino acids can be used as building blocks for the development of new drugs or the modification of existing ones to improve their efficacy, bioavailability, or reduce side effects.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-Bromo-4-methylpentanoic Acid Methyl Ester serves as a versatile reagent that can be employed in the creation of a wide range of organic compounds. Its unique structural features make it a valuable component in the synthesis of complex molecules, including those with potential applications in materials science, agrochemicals, and other specialty chemicals.
Used in Research and Development:
2-Bromo-4-methylpentanoic Acid Methyl Ester is also utilized in research and development settings, where it can be explored for its potential in creating novel compounds with specific biological activities or material properties. Its use in this context is driven by the need for new and innovative molecules to address various challenges in science and technology.

Upstream product

• 67-56-1 methanol 
• 646-07-1 4-Methylpentanoic acid 
• 38136-29-7 4-methylvaleroyl chloride 
• 186581-53-3 diazomethane 
• 28659-87-2 2-Bromo-4-methylpentanoic Acid 
• 328-39-2 LEUCINE 
• 61-90-5 L-leucine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 28659-88-3 2-bromo-4-methylpentanoyl chloride 

Downstream Products

• 756870-07-2 2-(4-bromo-phenoxy)-4-methyl-pentanoic acid methyl ester 
• 756869-96-2 2-(2-bromo-phenoxy)-4-methyl-pentanoic acid methyl ester 
• 756870-08-3 2-(3-bromo-phenylsulfanyl)-4-methyl-pentanoic acid methyl ester 
• 756869-97-3 2-(2-bromo-phenylsulfanyl)-4-methyl-pentanoic acid methyl ester 
• 1279699-94-3 3-bromo-5-methyl-1-[(R)-p-tolylsulfinyl]hexan-2-one 
• 1279699-97-6 (S)-3-(dibenzylamino)-5-methyl-1-[(R)-p-tolylsulfinyl]hexan-2-one 
• 1279700-01-4 (2R,3S)-3-(dibenzylamino)-5-methyl-1-[(R)-p-tolylsulfinyl]hexan-2-ol 
• 171815-93-3 (2R,1'S)-2-[1-(dibenzylamino)-3-methylbutyl]oxirane 
• 1380287-32-0 2-(6-chloro-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester 
• 756870-06-1 2-(3-bromo-phenoxy)-4-methyl-pentanoic acid methyl ester 
• 86895-67-2 methyl 4-methyl-2-phenylthiopentanoate 

Relevant academic research and scientific papers

Enantioselective Synthesis of Quaternary α-Amino Acids Enabled by the Versatility of the Phenylselenonyl Group

A novel Cinchona alkaloid-catalyzed enantioselective conjugate addition of α-alkyl substituted α-nitroacetates to phenyl vinyl selenone was developed. The resulting enantio-enriched α,α-dialkyl substituted α-nitroacetates were subsequently converted to various cyclic and acyclic quaternary α-amino acids, taking advantage of the rich functionalities of the resulting Michael adducts. Novel protocols allowing chemoselective reduction of phenyl selenone to phenyl selenide and reduction of alkyl phenyl selenones to alkanes are also reported.

Enantioselective construction of tetrasubstituted stereogenic carbons through bronsted base catalyzed michael reactions: α′-hydroxy enones as key enoate equivalent

Catalytic and asymmetric Michael reactions constitute very powerful tools for the construction of new C-C bonds in synthesis, but most of the reports claiming high selectivity are limited to some specific combinations of nucleophile/electrophile compound types, and only few successful methods deal with the generation of all-carbon quaternary stereocenters. A contribution to solve this gap is presented here based on chiral bifunctional Bronsted base (BB) catalysis and the use of α′-oxy enones as enabling Michael acceptors with ambivalent H-bond acceptor/donor character, a yet unreported design element for bidentate enoate equivalents. It is found that the Michael addition of a range of enolizable carbonyl compounds that have previously demonstrated challenging (i.e., α-substituted 2-oxindoles, cyanoesters, oxazolones, thiazolones, and azlactones) to α′-oxy enones can afford the corresponding tetrasubstituted carbon stereocenters in high diastereo- and enantioselectivity in the presence of standard BB catalysts. Experiments show that the α′-oxy ketone moiety plays a key role in the above realizations, as parallel reactions under identical conditions but using the parent α,β-unsaturated ketones or esters instead proceed sluggish and/or with poor stereoselectivity. A series of trivial chemical manipulations of the ketol moiety in adducts can produce the corresponding carboxy, aldehyde, and ketone compounds under very mild conditions, giving access to a variety of enantioenriched densely functionalized building blocks containing a fully substituted carbon stereocenter. A computational investigation to rationalize the mode of substrate activation and the reaction stereochemistry is also provided, and the proposed models are compared with related systems in the literature.

ISATIN AND OXINDOLE COMPOUNDS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Highly enantioselective access to α-dibenzylamino ketones from chiral nonracemic α-bromo α′-sulfinyl ketones by dynamic kinetic resolution: Synthesis of (2R,1′S)-2-[1-(dibenzylamino)alkyl]oxiranes

A novel and efficient synthesis of enantiomerically pure α-dibenzylamino α′-sulfinyl ketones starting from a mixture of both epimers of α-bromo α′-(R)-sulfinyl ketone has been realized through combined in situ substitution-epimerization in a so-called Dynamic Kinetic Resolution (DKR). The scope of the reaction has been examined, and four differently substituted α-(S)-dibenzylamino α′-(R)- sulfinyl ketones were obtained in good yields with excellent diastereoselectivities. The utility of these derivatives was further illustrated with a highly stereoselective synthesis of syn-(2R,1′S)-2-(1- dibenzylaminoalkyl)oxiranes.

PYRIDONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful

BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

PYRIDAZINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).

Homologation of large rings

Free radical-promoted, one-carbon, ring expansion of twelve, fourteen-, and fifteen-membered cyclic β-keto esters is described. The method is then extended to include a three-carbon ring expansion of cyclododecanone, the targets being (±)-muscone and natu